positive
3 days agoCorona Remedies IPO allotment completed amid strong demand
Investor attention remains on the pharmaceutical sector as Corona Remedies finalised share allotment following heavy subscription. The Rs 655.37 crore IPO was subscribed 137.04 times overall, with QIBs bidding 278.52 times, NIIs 208.88 times and retail investors 28.73 times. The issue was a pure offer for sale by existing shareholders. Grey market premium is around Rs 305, indicating an expected listing near Rs 1,367, or roughly 29 percent above the upper issue price of Rs 1,062.
Tags:
- corona remedies
- ipo allotment
Explore:Mutual Fund Tools
positive
3 days agoCorona Remedies IPO allotment completed amid strong demand
Investor attention remains on the pharmaceutical sector as Corona Remedies finalised share allotment following heavy subscription. The Rs 655.37 crore IPO was subscribed 137.04 times overall, with QIBs bidding 278.52 times, NIIs 208.88 times and retail investors 28.73 times. The issue was a pure offer for sale by existing shareholders. Grey market premium is around Rs 305, indicating an expected listing near Rs 1,367, or roughly 29 percent above the upper issue price of Rs 1,062.
Tags:
- corona remedies
- ipo allotment
Explore:Mutual Fund Tools
Recently
1 min read
76 words
Corona Remedies’ IPO allotment was finalised after strong demand, with grey market trends pointing to a near 29 percent premium at listing.
Investor attention remains on the pharmaceutical sector as Corona Remedies finalised share allotment following heavy subscription. The Rs 655.37 crore IPO was subscribed 137.04 times overall, with QIBs bidding 278.52 times, NIIs 208.88 times and retail investors 28.73 times. The issue was a pure offer for sale by existing shareholders. Grey market premium is around Rs 305, indicating an expected listing near Rs 1,367, or roughly 29 percent above the upper issue price of Rs 1,062.
Investor attention remains on the pharmaceutical sector as Corona Remedies finalised share allotment following heavy subscription. The Rs 655.37 crore IPO was subscribed 137.04 times overall, with QIBs bidding 278.52 times, NIIs 208.88 times and retail investors 28.73 times. The issue was a pure offer for sale by existing shareholders. Grey market premium is around Rs 305, indicating an expected listing near Rs 1,367, or roughly 29 percent above the upper issue price of Rs 1,062.
Tags:
- corona remedies
- ipo allotment
- corona remedies
- ipo allotment
- gmp
- pharma stocks
Dec 12, 2025 • 04:56